PSA as a Marker for Prostate Cancer: A Critical Review

Hara H Koyangagi Y Inoue T Fukuyama T. Some physiochemical characteristics of gamma-semino-protein: An antigenic component specific for human seminal plasma. Jpn J Legal Med 1971; 25: 322–4.

Sensabaugh GF Crim D. Isolation and characterization of a semen-specific protein from human seminal plasma: A potential new marker for semen identification. J Forensic Sci 1978; 23: 106–15.

Wang MC Valenzuela LA Murphy GP Chu TM . Purification of a human prostate specific antigen. Invest Urol 1979; 17: 154–63.

Peehl D. Prostate specific antigen role and function. Cancer 1995; 75: 2021–6.

Henttu P Lukkarinen O Vihko P. Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate. Int J Cancer 1990; 45: 654–60.

Armbruster DA . Prostate specific antigen: Biochemistry, analytical methods and clinical application. Clin Chem 1993; 39: 181–95.

Lilja H Christensson A Dahlen U Matikainen M-T Nilsson O Pettersson K Prostate-specific antigen in serum occurs predominantly in complexes with α1-antichymotrypsin. Clin Chem 1991; 37: 1618–25.

Denis LJ Murphy GP Schroder FH . Report on the consensus workshop on screening and global strategy for prostate cancer. Cancer 1995; 75: 1187–207.

Lilja H . A kallikrein-like serine protease in prostate fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985; 76: 1899–903.

Cohen P Graves H Peehl DM Kamarei M Giudice LC Rosenfeld RG . Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992; 75: 1046–53.

Webber MM Waghray A Bells D. Prostate specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1995; 1: 1089–94.

Duffy MJ . Urokinase plasminogen activator and malignancy. Fibronolysis 1993; 7: 295–302.

Graves HCB . Nonprostatic sources of prostate-specific antigen. Clin Chem 1995; 41: 7–9.

Yu H Diamandis EP . Prostate-specific antigen immunoreactivity in amniotic fluid. Clin Chem 1995; 41: 204–10.

Yu H Diamandis EP . Prostate-specific antigen in milk of lactating women. Clin Chem 1995; 41: 54–8.

Schroder FH . Prostate cancer: To screen or not to screen? BMJ 1993; 306: 407–8.

Oesterling JE . Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907–23.

Ciatto S Bonardi R Mazzotta A Zappa M. Evidence and feasibility of prostate cancer screening. Cancer J 1995; 8: 33–5.

Kojima M Babaian RJ . Algorithms for early detection of prostate cancer. Cancer 1995; 75: 1860–8.

Catalona WJ Smith DS Ratliff TL Dodds KM Coplen DE Yuan JJ . Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156–61.

Catalona WJ Smith DS Ratliff TL Basher JW . Detection of organ-confirmed prostate cancer is increased through prostate specific antigen-based screening. JAMA 1993; 270: 948–54.

Oesterling JE . Prostate specific antigen, its role in the diagnosis and staging of prostate cancer. Cancer 1995; 75: 1795–804.

Tibblin G Wellin L Bergstrom R Ronquist G Norlen B-J Adami H-O. The value of prostate specific antigen in early diagnosis of prostate cancer: The study of men born in 1913. J Urol 1995; 154: 1386–9.

Gann PH Hennekens CH Stampfer MJ . A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 289–94.

Tabar L Fagerberg G Duffy SW Day NE Gad A Grontoft O. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am 1992; 30: 187–210.

Partin AW Carter HB Chan DW Epstein JI Oesterling JE Rock RC Prostate specific antigen in the staging of localised prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143: 747–52.

Sershon PD Barry MJ Oesterling JE . Serum PSA values in men with histologically confirmed BPH versus patients with organ fixed prostate cancer. Eur Urol 1994; 25: 281–7.

Stamey T Yang N Hay AR McNeal JE Freiha FS Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909–16.

Benson MC Whang IS Olsson CA McMahon DJ Cooner WH . The use of prostate specific antigen density to enhance the predictive value of intermedial levels of serum prostate specific antigen. J Urol 1992; 147: 817–21.

Benson MC Olsson CA . Prostate specific antigen and prostate specific antigen density, roles in patient evaluation and management. Cancer 1994; 74: 1667–73.

Rommel FM Agusta VE Breslin JA Huffnagle HW Pohl CE Sieber PR The use of prostate-specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community-based urology practice. J Urol 1994; 151: 88–93.

Richie JP Catalona WC DeKernion JB Ahmann FR Ratliff TL Dulkin BL . Evaluation of prostate-specific antigen density in the early detection of prostate cancer: Results of a prospective multicenter clinical trial of 4962 men. J Urol 1994; 151: 303A.

Brawer MK Aramburu EA Chen GL Preston SD Ellis WJ . The inability of prostate-specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostate carcinoma. J Urol 1993; 150: 369–73.

Carter HB Pearson JD Metter J Brant L Chan DW Andres R Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215–20.

Catalona W Smith D Ratliff T. Value of measurements of the rate of change of serum PSA levels in prostate cancer screening. J Urol 1993; 148: 449A.

Riehmann M Rhodes P Grose G Bruskewitz R. Unexpected variation in PSA values. J Urol 1993; 148: 449A.

Wu JT . Assays for prostate specific antigen (PSA): Problems and possible solutions. J Clin Lab Anal 1994; 8: 51–62.

Oesterling JE Jacobsen SJ Chute CG Guess HA Girman CJ Panser LA Serum prostate-specific antigen in a community-based population of healthy men. JAMA 1993; 270: 860–4.

Oesterling JE Mumanoto Y Tsukamoto T Girman CJ Guess HA Masunori N Serum prostate-specific antigen in a community-based population of healthy Japanese men: Lower values than for similarly aged white men. Br J Urol 1995; 75: 347–53.

Lankford SP Peters KL Elser RC . Potential Effects of age-specific reference ranges for serum prostate-specific antigen. Eur Urol 1995; 27: 182–6.

Stenman UH Leinonen J Alfthan H Rannikko S Tuhkanen K Alfthan O. A complex between prostate-specific antigen in serum and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222–6.

Stenman H-H Hakama M Knekt P Aromaa A Teppo L Leinonen J. Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis in prostate cancer. Lancet 1994; 344: 1594–8.

Mitrunen K Pettersson K Piironen T Bjork T Lilja H Lovgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 1995; 41: 1115–20.

Catalona WJ Smith DS Wolfert RL Wang TJ Rittenhouse HG Ratliff TL Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214–20.

Gleason DF . Classification of prostatic carcinomas. Cancer Chemother Rep 1966; 50: 125–30.

Pettersson K Piironen T Seppala M Liukkonen L Christensson A Matikainen M-T Free and complexed prostate-specific antigen (PSA): In vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-α¹-antichymotrypsin complex. Clin Chem 1995; 41: 1480–8.

Gerber GS Thompson IM Thisted R Chodak GW . Disease specific survival following routine prostate cancer screening by digital rectal examination. JAMA 1993; 269: 61–4.

Krahn MD Mahoney JE Eckman MH Trachtenberg J Pauker SG Detsky AS . Screening for prostate cancer, a decision analytic view. JAMA 1994; 272: 773–80.

Scardino PT . Early detection of prostate cancer. Urol Clin N Am 1988; 140: 1445–7.

Graham SD . Screening for prostate cancer. Cancer 1994; 74: 3077–9.

Optenberg SA Thompson IM . Economics of screening for carcinoma of the prostate. Urol Clin N Am 1990; 17: 719–37.

Narod S Dupont A Cusan L Diamond P Gomez J-L Suburu R The impact of family history on early detection of prostate cancer. Nature Med 1995; 1: 99–101.

Katz AE Olison CA Raffo AJ Cama C Perlman H Seaman E Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 1994; 43: 765–75.

Deguchi T Doi T Ehara H Shinichi I Takahashi Y Nishino Y Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1993; 53: 5350–4.

Wood DP Jr Banks ER Humphreys S McRoberts JW Rangnekar VM . Identification of bone marrow micrometastases in patients with prostate cancer. Cancer 1994; 74: 2533–40.

Dillioglugil O Miles BJ Scardino PT . Current controversies in the management of localized prostate cancer. Eur Urol 1995; 28: 85–101.

Vessella RL . Trends in immunoassays of prostate-specific antigen: Serum complexes and ultra-sensitivity. Clin Chem 1993; 39: 2035–9.

Lange PH Ercole CJ Lightner DJ Fraley EE Vessella R. The value of prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989; 141: 873–9.

Frazier HA Robertson JE Humphrey PA Paulson DF . Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol 1993; 149: 516–8.

Zagars GK Pollack A. The fall and rise of prostate-specific antigen, kinetics of serum prostate-specific antigen after radiation therapy for prostate cancer. Cancer 1993; 72: 832–42.

Schmid H-P. Tumour markers in patients on deferred treatment: Prostate specific antigen doubling times. Cancer Sur 1995; 23: 157–67.

Matzkin H Eber P Todd B van der Zwaag R Soloway MS . Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer 1992; 70: 2302–9.